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Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strategies with
higher clinical efficacy are being actively sought. ‘Immunotherapy’ is now emerging as one such promising
strategy for the treatment of these tumors. This article briefly reviews the recent advances that utilize targeting of
immune checkpoint pathways, in the management of gastrointestinal malignancies.
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Gastrointestinal (GI) cancers are a group of highly ag-
gressive malignancies and a major public health problem
worldwide. In the USA alone, 291,000 new cases are
estimated to be diagnosed, and approximately 149,000
patients will die from these cancers in 2015 [1]. The
currently approved treatments for these tumors result in
only modest improvement in overall survival (OS), espe-
cially when dealing with advanced disease. Consequently,
novel therapeutic strategies with higher efficacy are
being actively sought.
Immunotherapy is a relatively new and evolving field
of cancer therapeutics that has already demonstrated
durable responses in solid tumors including melanoma,
non-small cell lung cancer, and renal cancer and is asso-
ciated with encouraging activity in hematologic malig-
nancies as well [2, 3]. In contrast, the progress made
towards development of effective antitumor immune
therapies for GI cancers has been relatively slow. GI ma-
lignancies usually lack naturally occurring effector T cell
responses and have been traditionally considered to be
poorly immunogenic. With the identification of new* Correspondence: sunw@upmc.edu
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immunotherapy is now beginning to emerge as a prom-
ising therapeutic strategy [4, 5]. This article highlights
the recent immunotherapeutic advances that were
witnessed in the field of GI malignancies.Immune checkpoint blockade
It is now well established that tumors evade the host im-
mune response using a multitude of mechanisms, includ-
ing expansion of immunosuppressive cells (regulatory T
[Treg] cells, myeloid-derived suppressor cells [MDSCs]) in
the tumor microenvironment, elaboration of various cyto-
kines and chemokines (transforming growth factor-β
[TGF-β], interleukin [IL]-10, indoleamine 2,3-dioxygenase
[IDO]), and co-inhibitory signaling pathways mediated via
immune checkpoints (cytotoxic T lymphocyte-associated
protein-4 [CTLA-4], programmed cell death-1 [PD-1],
T cell immunoglobulin- and mucin-domain-containing
molecule-3 [TIM-3], and lymphocyte activation gene 3
[LAG3]) [6]. Together, these contribute to the develop-
ment of resistance to immune effectors.
Immune checkpoint blockade strategy is now being
actively evaluated in the management of GI malignan-
cies including esophageal, gastric, colorectal, and liver
cancers. PD-1, which is a co-inhibitory receptor expressed
on the surface of activated T cells, B cells, and myeloid
cells, interacts with its ligands (PD-L1 and PD-L2) to pre-
vent T cell functioning. Antibody mediated blockade ofarticle distributed under the terms of the Creative Commons Attribution License
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leading to T cell functional activation and enhanced anti-
tumor activity. Emerging data suggest encouraging activity
of PD-1 axis blockade in the management of GI cancers.
Gastric and esophageal carcinoma
The Cancer Genome Atlas (TCGA) project performed
comprehensive molecular characterization of gastric
adenocarcinoma and identified four major molecular sub-
types, namely, Epstein-Barr virus (EBV)-infected tumors,
microsatellite instability (MSI) tumors, genomically stable
tumors, and chromosomally unstable tumors [7]. In the
EBV subgroup, there was amplification at 9p24.1 leading
to upregulation of PD-L1 and PD-L2, which indicates a
potential role of PD-1 axis blockade in treatment of these
patients.
KEYNOTE-012 is a multi-center, multi-cohort, non-
randomized phase Ib trial evaluating the safety and effi-
cacy of anti-PD-1 antibody pembrolizumab (MK-3475) in
patients with previously treated, PD-L1-positive, advanced
cancers (NCT01848834) [8]. Patients were classified as
PD-L1 positive based on ≥1 % of tumor cells demonstrat-
ing expression of PD-L1 marker, or any positive staining
in the tumor stroma. In the gastric cancer cohort, 39
patients who were previously treated for their metastatic
diseases have been enrolled. The observed median dur-
ation of response (DoR) was 24 weeks. The 6-month pro-
gression free survival (PFS) and OS rates were 24 and
69 %, respectively. PD-L1 expression level was found to
correlate with the objective response rate (ORR; P = 0.10).
In this study cohort, four patients experienced grades 3–5
drug-related adverse events (DRAEs), which included per-
ipheral sensory neuropathy, fatigue, decreased appetite,
hypoxia, and pneumonitis. In another similar multi-
cohort, phase Ib trial (KEYNOTE-028) of pembrolizumab
monotherapy for PD-L1-positive advanced solid tumors,
23 patients with either squamous cell carcinoma (SCC;
74 %) or adenocarcinoma (22 %) of the esophagus or gas-
troesophageal junction (GEJ) have been treated at the time
of interim analysis (NCT02054806) [9]. The ORR was
30 % (40 % for adenocarcinoma, 29 % for SCC). The me-
dian DoR was 40 weeks, with 6 of 7 responses ongoing at
cutoff. DRAEs were observed in 39 %, including grade 3
toxicity (lymphopenia, decreased appetite, liver disorder,
pruritic rash) in 17 % (n = 4) of the patients.
In summary, the available results from KEYNOTE-012
and KEYNOTE-028 demonstrate a promising clinical ac-
tivity of pembrolizumab monotherapy in heavily pre-
treated, PD-L1-positive, advanced gastric and esophageal
carcinoma, respectively.
Colorectal cancer
MSI tumors are characterized by epigenetic silencing or
mutations of DNA mismatch repair (MMR) genes, leadingto the formation of variable length DNA microsatellites.
The high mutational load in MSI tumors creates many
tumor-specific neoantigens, some of which are recognized
as foreign by T cells, and this contributes to the lympho-
cytic reaction frequently observed in these tumors [10].
MSI colorectal cancers (CRCs) comprise approximately
15 % of the total sporadic CRCs, and these tumors have
been shown to upregulate expression of immune check-
points including PD-1, PD-L1, CTLA-4, LAG-3, and IDO
in tumor infiltrating lymphocytes (TILs), stroma or tumor
invasive front compartments [11].
A phase II study evaluated the clinical activity of pem-
brolizumab monotherapy in patients with previously
treated, progressive metastatic tumors, with and without
MMR deficiency (NCT01876511) [12]. The patients were
enrolled in three cohorts, MMR-deficient CRC (n = 11),
MMR-proficient CRC (n = 21), and MMR-deficient non-
colorectal tumor cohort (n = 9). The study met its co-
primary endpoints of immune-related ORR (irORR) and
immune-related PFS (irPFS) at 20 weeks, for both the
MMR-deficient cohorts. The irORR and irPFS were 40
and 78 % for MMR-deficient CRC, 0 and 11 % in the
MMR-proficient CRC cohort. Response rates (RR) and
disease control rates (DCR) were 40 and 90 % in MMR-
deficient CRC, 0 and 11 % in MMR-proficient CRC
cohort. Median PFS and OS were not reached in the
MMR-deficient CRC group but was 2.2 and 5.0 months in
the MMR-proficient CRC cohort (hazard ratio [HR] for
PFS = 0.103; 95 % confidence interval [CI], 0.029 to 0.373;
P = 0.001 and HR for OS = 0.216; 95 % CI, 0.047 to 1.000;
P = 0.05). These results provide promising evidence to
suggest that MMR status predicts clinical benefit from im-
mune checkpoint blockade in advanced CRC.
Hepatocellular carcinoma
The liver is characterized by the presence of an im-
munosuppressive microenvironment and expression of
PD-L1 on sinusoidal endothelial and Kupffer cells. Anti-
PD-1 blockade strategy has demonstrated manageable
toxicity profile and preliminary evidence of efficacy in a
recently reported study involving advanced hepatocellular
carcinoma (HCC) patients [13]. This multiple ascending-
dose phase I/II study evaluated the safety and antitumor
efficacy of nivolumab in patients with pretreated or
sorafenib-intolerant advanced HCC (NCT01658878).
Patients with Child-Pugh score ≤B7 were enrolled in three
independent parallel cohorts, namely, uninfected, HCV-
infected, and HBV-infected cohorts. DRAEs occurred in
32 patients (68 %; 19 % grades 3–4) and included elevation
of lipase, amylase, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), rash, anemia, and fatigue.
No maximum tolerated dose (MTD) was identified in any
cohort. At the time of the interim analysis in March 2015,
response was evaluable in 42 patients and included two
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(PR; 14 %). Objective clinical responses were observed in
both uninfected and viral-associated HCC. The OS rate
was 70 % at 9 months and 62 % at 12 months. Responses
were ongoing in six of eight patients at the time of interim
analysis. Patient enrollment is continuing in the dose ex-
pansion phase of the study.
Pancreatic cancer
Checkpoint pathways are also being evaluated as immu-
notherapeutic targets for the treatment of pancreatic
cancer. However, due to an immunologically quiescent
microenvironment associated with these tumors, none
of the examined approaches have demonstrated a clinic-
ally meaningful benefit till date [14]. CD40 activation
can reverse immune suppression and drive antitumor T
cell responses. Agonist CD40 antibody has been used in
combination with gemcitabine in a phase I study to
shrink pancreatic ductal adenocarcinoma by stimulating
tumor macrophages against pancreatic cancer stroma
[15]. Single agent ipilimumab was evaluated in a phase II
trial of advanced pancreatic cancer and failed to demon-
strate an appreciable antitumor activity [16]. The com-
bination of ipilimumab with gemcitabine in advanced
pancreatic cancer is currently under phase Ib evalu-
ation (NCT01473940). A phase Ib/II trial is studying
the safety and immunological effect of neoadjuvant
chemoradiation therapy (CRT) added to pembrolizu-
mab in resectable or borderline resectable pancreatic
cancer (NCT02305186). Other strategies that are being
evaluated include combination of vaccine (GVAX, CRS-
207) with antibody against CTLA-4 (NCT01896869) or
PD-1 (NCT02243371).
Future directions, challenges, and conclusion
The potential of immunotherapy as a treatment modality
for GI malignancies has finally become a reality. How-
ever, the clinical benefit from these agents is restricted
to only a subset of patients, at least at the present time.
Moreover, these immune-modulating therapies are often
associated with immune-mediated toxicities. Conse-
quently, biomarkers are needed to refine patient selec-
tion for optimum clinical benefit and minimize toxicity
[17].
PD-L1 positivity has been used to select patient popu-
lation in KEYNOTE trials. Experience from a series of
clinical trials across a variety of tumor types suggests
that although PD-L1 positivity is associated with a
greater likelihood of response from anti-PD-1 or anti-
PD-L1 agents, the benefit is not restricted to the PD-L1-
positive population exclusively [18]. Currently, the evalu-
ation and validation of PD-L1 positivity as a predictive
biomarker suffers from several limitations including lack
of standardized definition for PD-L1 positivity, lack ofuniformity in antibody clone used for immunohistochem-
istry staining across studies, and discordance between pri-
mary tumor and metastatic lesions [18].
The presence of MSI is a potential genetic biomarker
shown to have a predictive value in the study presented
by Le and colleagues [12]. Considering the fact that ma-
jority of GI tumors are microsatellite stable (MSS) and
therefore immunogenically quiescent, additional ap-
proaches that utilize combination of immune checkpoint
inhibitors with T cell-inducing strategies such as use of
vaccines, chemotherapy, targeted agents, or radiotherapy
need to be evaluated to continually improve upon the
existing responses.
To conclude, immune therapy using checkpoint block-
ade has added a new treatment paradigm in the manage-
ment of GI malignancies. Further evaluation with future
clinical trials that enroll larger patient cohorts and study
combinatorial approaches is strongly warranted.
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